-transparent.png){kind=logo}
A number of adverse reactions have been associated with sulindac, a nonsteroidal anti-inflammatory drug, but acute hemolytic anemia associated with sulindac has not yet been reported, to our knowledge. We encountered two cases of severe immune hemolytic anemia, one fatal, which appear to have been related to sulindac. In vitro studies provided evidence that antibodies to sulindac and its metabolites were present in the serum of both patients.
Related Publications
F P Johnson, and
H E Hamilton, and
M R Liesch
August 1986,
Archives of internal medicine,
F P Johnson, and
H E Hamilton, and
M R Liesch
March 1994,
Transfusion,
F P Johnson, and
H E Hamilton, and
M R Liesch
January 1997,
Transfusion,
F P Johnson, and
H E Hamilton, and
M R Liesch
September 1985,
American journal of clinical pathology,
F P Johnson, and
H E Hamilton, and
M R Liesch
January 2004,
Transfusion,
F P Johnson, and
H E Hamilton, and
M R Liesch
November 1978,
Southern medical journal,
F P Johnson, and
H E Hamilton, and
M R Liesch
January 2010,
Blood reviews,
F P Johnson, and
H E Hamilton, and
M R Liesch
June 1987,
Clinical pharmacy,
F P Johnson, and
H E Hamilton, and
M R Liesch
February 2009,
Praxis,
F P Johnson, and
H E Hamilton, and
M R Liesch
March 1994,
La Revue de medecine interne,
